Non-small cell lung cancer (NSCLC) is recognized as one of the most aggressive cancers, and resistance to cisplatin significantly hinders effective clinical treatment. The role of the E3 ubiquitin ligase RNF180 in cisplatin resistance in NSCLC remains unclear. A549/DDP cells...
Abstract Osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, was developed to overcome resistance from EGFR-mutant non–small-cell lung cancer (NSCLC). While it offers significant therapeutic benefits, reports have linked Osimertinib to cardiotoxic effects. This study aims to clarify the...
Clinical Research: Chronic Kidney DiseaseFinerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR Insights from FINEARTS-HF Mc Causland, Finnian R.1; Heerspink, Hiddo J.L.2; Vaduganathan, Muthiah1; Claggett, Brian L.1; Desai, Akshay S.1; Jhund, Pardeep S.3; McGrath, Martina M.1;...
Abstract Natural alkaloids were computationally investigated as putative allosteric modulators of the epidermal growth factor receptor (EGFR) to explore alternative strategies for overcoming resistance associated with T790M and C797S mutations. Density functional theory (DFT), molecular docking, molecular dynamics (MD), and...
Interpreting Overall Survival and CNS Outcomes in EGFR Mutated Metastatic Non-Small Cell Lung Cancer Experts weigh EGFR lung cancer combo therapies, cautioning against cross-trial comparisons and prioritizing CNS efficacy for brain metastases. In this segment, Dr. Singhi discusses how overall...
Evolving First Line Treatment Goals in EGFR Mutated Metastatic Non-Small Cell Lung Cancer Experts unpack new EGFR-mutant lung cancer first-line options, weighing survival, CNS control, and toxicity as combo regimens reshape practice. In this opening segment, Dr. Devarakonda introduces the...
To investigate the molecular mechanism of Astragalus membranaceus (AM) in alleviating silicosis fibrosis using bioinformatics and in vitro experiments. Active ingredients of AM and their corresponding targets were retrieved from the TCMSP and SwissTargetPrediction databases. These ingredients were screened based...
AbstractBackground Leptomeningeal metastasis (LM) is a severe complication of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), associated with limited treatment options and poor prognosis. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), has demonstrated central nervous system...
Abstract Reports of secondary mutations in mutual exclusive driver genes after resistance to targeted therapy are rare. We present a patient with Anaplastic lymphoma kinase (ALK) fusion lung adenocarcinoma who received sequential treatment with ALK tyrosine kinase inhibitor (TKI) (crizotinib,...
